Complement Activation–Related Pseudoallergy (CARPA): An Underrecognized Risk of Drugs, Drug Carriers, and Formulation Vehicles

Kanchalit Thanomkitti, Antonella Tosti

Open source

DOI
10.1007/s12016-026-09212-z
Published
2026-10-31
Container
Clinical Reviews in Allergy & Immunology
Publisher
Springer Science and Business Media LLC
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s12016-026-09212-z,
  title = {Complement Activation–Related Pseudoallergy (CARPA): An Underrecognized Risk of Drugs, Drug Carriers, and Formulation Vehicles},
  author = {Kanchalit Thanomkitti and Antonella Tosti},
  year = {2026},
  journal = {Clinical Reviews in Allergy \& Immunology},
  doi = {10.1007/s12016-026-09212-z},
  url = {https://doi.org/10.1007/s12016-026-09212-z}
}

RIS

TY  - JOUR
TI  - Complement Activation–Related Pseudoallergy (CARPA): An Underrecognized Risk of Drugs, Drug Carriers, and Formulation Vehicles
AU  - Kanchalit Thanomkitti
AU  - Antonella Tosti
PY  - 2026
JO  - Clinical Reviews in Allergy & Immunology
DO  - 10.1007/s12016-026-09212-z
UR  - https://doi.org/10.1007/s12016-026-09212-z
ER  - 

APA

Thanomkitti, K., & Tosti, A. (2026). Complement Activation–Related Pseudoallergy (CARPA): An Underrecognized Risk of Drugs, Drug Carriers, and Formulation Vehicles. Clinical Reviews in Allergy & Immunology. https://doi.org/10.1007/s12016-026-09212-z

Source records